Kelly Scaggs Campen
Examiner (ID: 2758, Phone: (571)272-6740 , Office: P/3691 )
Most Active Art Unit | 3691 |
Art Unit(s) | 3624, 2165, 2164, 3312, 3738, 3691 |
Total Applications | 1052 |
Issued Applications | 501 |
Pending Applications | 228 |
Abandoned Applications | 322 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18545312
[patent_doc_number] => 11718652
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-08
[patent_title] => Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/327494
[patent_app_country] => US
[patent_app_date] => 2021-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 21
[patent_no_of_words] => 24129
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327494
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/327494 | Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof | May 20, 2021 | Issued |
Array
(
[id] => 17126245
[patent_doc_number] => 20210301013
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators
[patent_app_type] => utility
[patent_app_number] => 17/318875
[patent_app_country] => US
[patent_app_date] => 2021-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18966
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17318875
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/318875 | Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators | May 11, 2021 | Pending |
Array
(
[id] => 17035018
[patent_doc_number] => 20210251976
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
[patent_app_type] => utility
[patent_app_number] => 17/308869
[patent_app_country] => US
[patent_app_date] => 2021-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28986
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308869
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/308869 | Tryptamine compositions for enhancing neurite outgrowth | May 4, 2021 | Issued |
Array
(
[id] => 17258522
[patent_doc_number] => 20210371507
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => ANTI-TRANSTHYRETIN ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/307968
[patent_app_country] => US
[patent_app_date] => 2021-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37524
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17307968
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/307968 | Anti-transthyretin antibodies | May 3, 2021 | Issued |
Array
(
[id] => 17505492
[patent_doc_number] => 20220098594
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => COMPOSITIONS COMPRISING SASP MODULATORS AND SENESCENCE ATTENUATORS AND USES THEREOF FOR MODULATING CELLULAR SENESCENCE
[patent_app_type] => utility
[patent_app_number] => 17/302113
[patent_app_country] => US
[patent_app_date] => 2021-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35085
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17302113
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/302113 | COMPOSITIONS COMPRISING SASP MODULATORS AND SENESCENCE ATTENUATORS AND USES THEREOF FOR MODULATING CELLULAR SENESCENCE | Apr 22, 2021 | Pending |
Array
(
[id] => 17007106
[patent_doc_number] => 20210238267
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G
[patent_app_type] => utility
[patent_app_number] => 17/234658
[patent_app_country] => US
[patent_app_date] => 2021-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21590
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17234658
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/234658 | TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G | Apr 18, 2021 | Pending |
Array
(
[id] => 17005474
[patent_doc_number] => 20210236635
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => EGFR TARGETED THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/233805
[patent_app_country] => US
[patent_app_date] => 2021-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11675
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17233805
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/233805 | EGFR TARGETED THERAPY | Apr 18, 2021 | Pending |
Array
(
[id] => 18575532
[patent_doc_number] => 11732046
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-22
[patent_title] => Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease
[patent_app_type] => utility
[patent_app_number] => 17/222370
[patent_app_country] => US
[patent_app_date] => 2021-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 90
[patent_no_of_words] => 79176
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222370
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/222370 | Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease | Apr 4, 2021 | Issued |
Array
(
[id] => 17299521
[patent_doc_number] => 20210395360
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => SP35 Antibodies And Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/217263
[patent_app_country] => US
[patent_app_date] => 2021-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59265
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17217263
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/217263 | SP35 Antibodies And Uses Thereof | Mar 29, 2021 | Abandoned |
Array
(
[id] => 17052218
[patent_doc_number] => 20210261652
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => ANTIBODIES RECOGNIZING TAU
[patent_app_type] => utility
[patent_app_number] => 17/181997
[patent_app_country] => US
[patent_app_date] => 2021-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53464
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181997
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/181997 | Antibodies recognizing tau | Feb 21, 2021 | Issued |
Array
(
[id] => 16885421
[patent_doc_number] => 20210171616
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => ANTI-PACAP ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/175870
[patent_app_country] => US
[patent_app_date] => 2021-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7859
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175870
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/175870 | ANTI-PACAP ANTIBODY | Feb 14, 2021 | Abandoned |
Array
(
[id] => 18369125
[patent_doc_number] => 11649279
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-16
[patent_title] => Anti-complement factor C1Q antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/172807
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 10
[patent_no_of_words] => 35365
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172807
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/172807 | Anti-complement factor C1Q antibodies and uses thereof | Feb 9, 2021 | Issued |
Array
(
[id] => 17022326
[patent_doc_number] => 20210246197
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => ANTI-THYMOCYTE GLOBULIN
[patent_app_type] => utility
[patent_app_number] => 17/171480
[patent_app_country] => US
[patent_app_date] => 2021-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11388
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17171480
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/171480 | ANTI-THYMOCYTE GLOBULIN | Feb 8, 2021 | Abandoned |
Array
(
[id] => 16990277
[patent_doc_number] => 20210228697
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS
[patent_app_type] => utility
[patent_app_number] => 17/165638
[patent_app_country] => US
[patent_app_date] => 2021-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 81237
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165638
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/165638 | Personalized immunotherapy against several neuronal and brain tumors | Feb 1, 2021 | Issued |
Array
(
[id] => 17814332
[patent_doc_number] => 11419921
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-23
[patent_title] => Methods of treating neurological disorders
[patent_app_type] => utility
[patent_app_number] => 17/153548
[patent_app_country] => US
[patent_app_date] => 2021-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 29
[patent_no_of_words] => 23967
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153548
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/153548 | Methods of treating neurological disorders | Jan 19, 2021 | Issued |
Array
(
[id] => 17096929
[patent_doc_number] => 20210284720
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => METHODS OF TREATING NEURODEGENERATIVE DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/150201
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23744
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150201
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150201 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Jan 14, 2021 | Pending |
Array
(
[id] => 16976252
[patent_doc_number] => 20210220489
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => AMYGDALAR NEURAL ENSEMBLE THAT ENCODES THE UNPLEASANTNESS OF PAIN
[patent_app_type] => utility
[patent_app_number] => 17/148377
[patent_app_country] => US
[patent_app_date] => 2021-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32064
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17148377
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/148377 | AMYGDALAR NEURAL ENSEMBLE THAT ENCODES THE UNPLEASANTNESS OF PAIN | Jan 12, 2021 | Pending |
Array
(
[id] => 16915864
[patent_doc_number] => 20210188956
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => ANTI-TRANSTHYRETIN ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/127719
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29546
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127719
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/127719 | Anti-transthyretin antibodies | Dec 17, 2020 | Issued |
Array
(
[id] => 18134771
[patent_doc_number] => 11560424
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-24
[patent_title] => Antibodies to alpha-synuclein and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/111159
[patent_app_country] => US
[patent_app_date] => 2020-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 60
[patent_no_of_words] => 23642
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17111159
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/111159 | Antibodies to alpha-synuclein and uses thereof | Dec 2, 2020 | Issued |
Array
(
[id] => 16870584
[patent_doc_number] => 20210164051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN NEURAL-DERIVED EXOSOMES
[patent_app_type] => utility
[patent_app_number] => 17/110206
[patent_app_country] => US
[patent_app_date] => 2020-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27456
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17110206
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/110206 | METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN NEURAL-DERIVED EXOSOMES | Dec 1, 2020 | Pending |